Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis.

Published on Apr 21, 2021in Cancer5.742
· DOI :10.1002/CNCR.33584
Adam B. Weiner14
Estimated H-index: 14
(NU: Northwestern University),
Eric V. Li2
Estimated H-index: 2
(NU: Northwestern University)
+ 2 AuthorsEdward M. Schaeffer59
Estimated H-index: 59
(NU: Northwestern University)
BACKGROUND More than 3.6 million men in the United States harbor a diagnosis of prostate cancer (PCa). The authors sought to provide in-depth analyses of the causes of death for contemporary survivors. METHODS The authors performed a population-based cohort study in the United States (2000-2016) to assess causes of death for men diagnosed with PCa stratified by demographics and tumor stage. Using general population data, they calculated standardized mortality ratios (SMRs) as observed-to-expected death ratios. RESULTS In total, 752,092 men with PCa, including 200,302 who died (27%), were assessed. A total of 29,048 men with local/regional disease (17%) died of PCa, whereas more than 4-fold men died of other causes (n = 143,719 [83%]). SMRs for death from noncancer causes (0.77; 95% confidence interval [CI], 0.77-0.78) suggested that these men were less likely than the general population to die of most other causes. The most common noncancer cause of death was cardiac-related (23%; SMR, 0.76; 95% CI, 0.75-0.77). Among men with distant PCa, 90% of deaths occurred within 5 years of diagnosis. Although deaths due to PCa composed the majority of deaths (74%), SMRs suggested that men with distant PCa were at heightened risk for death from most other noncancer causes (1.50; 95% CI, 1.46-1.54) and, in particular, for cardiac-related death (SMR, 1.48; 95% CI, 1.41-1.54) and suicide (SMR, 2.32; 95% CI, 1.78-2.96). Further analyses demonstrated that causes of death varied by patient demographics. CONCLUSIONS Causes of death during PCa survivorship vary by patient and tumor characteristics. These data provide valuable information regarding health care prioritization during PCa survivorship. LAY SUMMARY Men with early-stage prostate cancer are 4-fold more likely to die of other causes, whereas those with advanced prostate cancer are at increased risk for several causes not related to prostate cancer in comparison with the general population. These findings can help guide physicians taking care of men with a diagnosis of prostate cancer.
📖 Papers frequently viewed together
27 Citations
7 Authors (Chang-Mo Oh, ..., Hyunsoon Cho)
12 Citations
4 Citations
#1Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
#2MaryBeth B. Culp (ACS: American Cancer Society)H-Index: 3
Last. Stacey A. Fedewa (ACS: American Cancer Society)H-Index: 43
view all 5 authors...
BACKGROUND: Previous studies reported that prostate cancer incidence rates in the United States (US) declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged ≥75 in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016. METHODS: Based on the US Cancer Statistics Public Use Research Database, we e...
28 CitationsSource
#1Adam B. Weiner (NU: Northwestern University)H-Index: 14
#2Amanda X. Vo (NU: Northwestern University)H-Index: 1
Last. Edward M. Schaeffer (NU: Northwestern University)H-Index: 59
view all 6 authors...
BACKGROUND: The objective of this study was to determine the effect of Medicaid expansion under the Patient Protection and Affordable Care Act (January 1, 2014) on the epidemiology of high-risk prostate-specific antigen (PSA) levels (>/=20 ng/mL) at the time of prostate cancer (PCa) diagnosis. The authors hypothesized that better access to care would result in a reduction of high-risk features at diagnosis. METHODS: A retrospective cohort study was performed of 122,324 men aged /=20 ng/mL increa...
5 CitationsSource
#1Neal D. ShoreH-Index: 56
#2Fred SaadH-Index: 98
Last. Bertrand TombalH-Index: 49
view all 14 authors...
Abstract Background Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial t...
71 CitationsSource
#1H. Gilbert WelchH-Index: 74
#1H. Gilbert Welch (Brigham and Women's Hospital)H-Index: 4
Last. Peter C. AlbertsenH-Index: 75
view all 2 authors...
Reconsidering Prostate Cancer Mortality Since PSA screening and the treatment that may follow result in trading off one cause of death for another, rather than extending life, providers who support...
28 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 28
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statis...
6,326 CitationsSource
#1H. Gilbert Welch (Brigham and Women's Hospital)H-Index: 4
#1H. Gilbert WelchH-Index: 74
Last. William C. BlackH-Index: 31
view all 3 authors...
Interpreting Cancer Mortality The authors use 40 years of data on cancer incidence and mortality to produce curves that show changes in cancer incidence (decreasing, increasing, or staying stable) ...
45 CitationsSource
#1Kimberly D. Miller (ACS: American Cancer Society)H-Index: 28
#2Leticia Nogueira (ACS: American Cancer Society)H-Index: 15
Last. Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
view all 9 authors...
: The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; ...
1,141 CitationsSource
#1Marco Moschini (Medical University of Vienna)H-Index: 27
#2Emanuele Zaffuto (UdeM: Université de Montréal)H-Index: 16
Last. Shahrokh F. ShariatH-Index: 132
view all 11 authors...
Abstract Background Long-term survival can be achieved in patients affected by localized prostate cancer (PCa) treated with either radical prostatectomy (RP) or external beam radiotherapy (EBRT). However, development of a second primary tumor is still poorly investigated. Objective To investigate the impact of RP and EBRT on subsequent risk of developing bladder (BCa) and/or rectal cancer (RCa) among PCa survivors. Design, setting, and participants A total of 84397 patients diagnosed with locali...
22 CitationsSource
1 CitationsSource
#1Zhenlang Guo (Guangzhou University of Chinese Medicine)H-Index: 5
#2Shu GanH-Index: 3
Last. Shusheng WangH-Index: 3
view all 9 authors...
Whether the diagnosis of prostate cancer is a contributory psychological stress that causes excess risk of suicide among affected men remains controversial. We performed a meta-analysis of previous studies to investigate suicide incidence and associated risk factors among men diagnosed with prostate cancer. The MEDLINE, Embase, Cochrane Library, and PsycINFO databases were searched to identify eligible studies published before April 2018. The inverse variance method with random-effects modeling ...
9 CitationsSource
Cited By2
#1Mitchell M. Huang (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 2
#2Ridwan Alam (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 11
Last. Zeyad R. Schwen (Cleveland Clinic)H-Index: 2
view all 10 authors...
Abstract null null Background null For men on active surveillance (AS) for prostate cancer (PCa), disease progression and age-related changes in health may influence decisions about pursuing curative treatment. null null null Objective null To evaluate the predicted PCa and non-PCa mortality at the time of reclassification among men on AS, to identify clinical criteria for considering a transition from AS to watchful waiting (WW). null null null Design, setting, and participants null Patients en...